Samsung Biologics and Moderna have announced an agreement

Samsung Biologics and Moderna have announced an agreement for Fill-Finish Manufacturing of Moderna’s COVID-19 vaccine to enable global supply.

The technology shift will occur instantly at Samsung Biologics’ facilities in Incheon, South Korea, using a new production line equipped for aseptic fill-finish packaging and labelling services to support the production of millions of doses of Moderna’s COVID-19 vaccine. The vaccine is expected to be available in markets outside of the United States in the third quarter of 2021.

CEO of Samsung Biologics, John Rim, stated: “This vaccine is paramount to people around the world in the fight against the COVID-19 pandemic and we truly appreciate our client Moderna for entrusting and choosing to partner with Samsung Biologics for the fill and finish of this important vaccine. Due to the high level of urgency in supplying the vaccine to the global population, we have set immediate action plans and schedule to make mRNA-1273 available for commercial distribution in the early second half of 2021.”

Moderna’s Chief Technical Operations and Quality Officer, Juan Andres, stated: “We are pleased to partner with Samsung Biologics for this fill and finish manufacturing, which will help us continue to scale up our manufacturing capacity outside of the U.S. We and our manufacturing partners remain committed to defeating the COVID-19 pandemic.”